SPC24 is critical for anaplastic thyroid cancer progression

Yin, Huabin; Meng, Tong; Zhou, Lei; Chen, Haiyan; Song, Dianwen

doi:10.18632/oncotarget.15670

Cited by 20 publications

(14 citation statements)

References 21 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Silencing of Nuf2 suppressed tumor growth in glioma, pancreatic cancer, and colon cancer cells [ 11 – 13 ]. In breast, lung, and anaplastic thyroid cancer, SPC24 plays a role in promoting cancer progression [ 14 – 16 ]. Moreover, the up-regulation of SPC25 was observed in lung cancer, prostate cancer, and breast cancer, significantly enhancing the proliferation of these tumor cells [ 17 – 21 ].…”

Section: Introductionmentioning

confidence: 99%

SPC25 overexpression promotes tumor proliferation and is prognostic of poor survival in hepatocellular carcinoma

Zhang

Zhou

Xie

et al. 2020

Aging

View full text Add to dashboard Cite

Background: The nuclear division cycle 80 (NDC80) complex assures proper chromosome segregation during the cell cycle progression. SPC25 is a crucial component of NDC80, and its role in hepatocellular carcinoma (HCC) has been explored recently. This study characterized the differential expression of SPC25 in HCC patients of different races and HBV infection status. Methods: Expression patterns of SPC25 were evaluated in TCGA and Chinese HCC patients. Kaplan-Meier analysis was applied to examine the predictive value of SPC25. In vitro and in vivo functional assays were conducted to explore the role of SPC25 in HCC. Bioinformatics methods were applied to investigate the regulatory mechanisms of SPC25. Findings: The mRNA levels of SPC25 were up-regulated in HCC. SPC25 has a significantly higher transcriptional level in Asian patients than Caucasian patients. SPC25 promoted HCC cell proliferation in vitro and tumor growth in vivo by accelerating the cell cycle. We identified transcription factors, miRNAs, and immune cells that may interact with SPC25. Interpretation: The findings suggest that increased expression of SPC25 is associated with poor prognosis of HCC and enhances the proliferative capacity of HCC cells. SPC25 could serve as a valuable prognostic marker and a novel treatment target for HCC.

show abstract

Section: Introductionmentioning

confidence: 99%

SPC25 overexpression promotes tumor proliferation and is prognostic of poor survival in hepatocellular carcinoma

Zhang

Zhou

Xie

et al. 2020

Aging

View full text Add to dashboard Cite

show abstract

“…The enrichment of the Tgd_c21 cells in the ICT non-responders suggests an association with ICT resistance. The top Tgd_c21 marker genes are oncogenic by nature including RRM2 54 , BIRC5 ( Survivin ) 55 , SPC24 56 , 57 , UBE2C 58 , 59 , and CDCA5 60 . Pathway analysis revealed a significant reduction in ligand-receptor binding capacity, IFNα and IFNβ signaling, IFN-γ response, and immunoregulatory interactions of Tgd_c21 cells, suggesting that Tgd_c21 cells may be a type of ‘exhausted’ γδ T cell with impaired anti-tumor immune functions.…”

Section: Discussionmentioning

confidence: 99%

A gene expression signature of TREM2hi macrophages and γδ T cells predicts immunotherapy response

2020

View full text Add to dashboard Cite

Identifying factors underlying resistance to immune checkpoint therapy (ICT) is still challenging. Most cancer patients do not respond to ICT and the availability of the predictive biomarkers is limited. Here, we re-analyze a publicly available single-cell RNA sequencing (scRNA-seq) dataset of melanoma samples of patients subjected to ICT and identify a subset of macrophages overexpressing TREM2 and a subset of gammadelta T cells that are both overrepresented in the non-responding tumors. In addition, the percentage of a B cell subset is significantly lower in the non-responders. The presence of these immune cell subtypes is corroborated in other publicly available scRNA-seq datasets. The analyses of bulk RNA-seq datasets of the melanoma samples identify and validate a signature - ImmuneCells.Sig - enriched with the genes characteristic of the above immune cell subsets to predict response to immunotherapy. ImmuneCells.Sig could represent a valuable tool for clinical decision making in patients receiving immunotherapy.

show abstract

“…SPC24 was previously identified to be highly expressed in anaplastic thyroid cancer. Knockdown of SPC24 expression inhibited cell growth and invasion and promoted tumor cell apoptosis (Yin et al, 2017 ). SPC24 was also reported to be highly expressed in hepatocellular carcinoma and was an independent predictor of survival (Zhu et al, 2015 ).…”

Section: Discussionmentioning

confidence: 99%

Progression Risk Assessment of Post-surgical Papillary Thyroid Carcinoma Based on Circular RNA-Associated Competing Endogenous RNA Mechanisms

Han

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Background: Accurate risk assessment of post-surgical progression in papillary thyroid carcinoma (PTC) patients is critical. Exploring key differentially expressed mRNAs (DE-mRNAs) regulated by differentially expressed circular RNAs (circRNAs) via the ceRNA mechanism could help establish a novel assessment tool.Methods: ceRNA network was established based on differentially expressed RNAs and correlation analysis. DE-mRNAs within the ceRNA network associated with progression-free interval (PFI) of PTC were identified to construct a prognostic ceRNA regulatory subnetwork. least absolute shrinkage and selection operator (LASSO)–Cox regression was applied to identify hub DE-mRNAs and establish a novel DE-mRNA signature in predicting PFI of PTC.Results: Six hub DE-mRNAs, namely, CLCNKB, FXBO27, FXYD6, RIMS2, SPC24, and CDKN2A, were identified to be most significantly related to the PFI of PTC, and a prognostic DE-mRNA signature was proposed. A nomogram incorporating the DE-mRNA signature and clinical parameters was established to improve the progression risk assessment in post-surgical PTC, which was superior to the American Thyroid Association risk stratification system and distant Metastasis, patient Age, Completeness of resection, local Invasion, and tumor Size (MACIS) score American Joint Committee on Cancer staging system.Conclusions: Based on the circRNA-associated ceRNA RNA mechanism, a DE-mRNA signature and prognostic nomogram was established, which may improve the progression risk assessment in post-surgical PTC.

show abstract

SPC24 is critical for anaplastic thyroid cancer progression

Cited by 20 publications

References 21 publications

SPC25 overexpression promotes tumor proliferation and is prognostic of poor survival in hepatocellular carcinoma

SPC25 overexpression promotes tumor proliferation and is prognostic of poor survival in hepatocellular carcinoma

A gene expression signature of TREM2hi macrophages and γδ T cells predicts immunotherapy response

Progression Risk Assessment of Post-surgical Papillary Thyroid Carcinoma Based on Circular RNA-Associated Competing Endogenous RNA Mechanisms

Contact Info

Product

Resources

About